- Andrew G Affleck, consultant dermatologist
- Dermatology Department, Ninewells Hospital, NHS Tayside, Dundee, UK
- andrew.affleck@nhs.scot
The UK Medicines and Healthcare Products Regulatory Agency’s (MHRA’s) new legislation around the prescription of oral isotretinoin is disappointing.1
It is a sad day when evidence is not used to influence clinical practice, and instead disproportionate weight is given to the views of a minority with substantial personal agendas and emotional biases attending a stakeholder event. The silent majority of patients have not been heard. The opinions of dermatologists who have been the …